Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)

被引：0
|
作者：
Yau, T. [1 ]
Meyer, T. [2 ]
Kelley, R. K. [3 ]
Mangeshkar, M. [4 ]
Cheng, A-L. [5 ]
El-Khoueiry, A. B. [6 ]
Abou-Alfa, G. K. [7 ]
机构：
[1] Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China
[2] Royal Free Hosp, Oncol, London, England
[3] USCSF Hellen Diller Family Comprehens Canc Ctr, Med, San Francisco, CA USA
[4] Exelixis, Biostat, Alameda, CA USA
[5] Natl Taiwan Univ, Coll Med, Taipei, Taiwan
[6] Univ Southern Calif, Norris Comprehens Canc Ctr, Med Oncol, Los Angeles, CA USA
[7] Mem Sloan Kettering Canc Ctr, Oncol, 1275 York Ave, New York, NY 10021 USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
133P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
    Venerito, M.
    Kelley, R. K.
    Ryoo, B-Y
    Merle, P.
    Park, J-W
    Bolondi, L.
    Chan, S. L.
    Lim, H. Y.
    Baron, A.
    Parnis, F.
    Knox, J.
    Cattan, S.
    Yau, T.
    Lougheed, J. C.
    Milwee, S.
    El-Khoueiry, A. B.
    Cheng, A-L
    Meyer, T.
    Abou-Alfa, G. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 282 - 283
  • [32] Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).
    Kelley, Robin Kate
    Ryoo, Baek-Yeol
    Merle, Philippe
    Park, Joong-Won
    Bolondi, Luigi
    Chan, Stephen Lam
    Lim, Ho Yeong
    Baron, Ari David
    Parnis, Francis
    Knox, Jennifer
    Cattan, Stephane
    Yau, Thomas Cheung
    Lougheed, Julie
    Milwee, Steven
    El-Khoueiry, Anthony
    Cheng, Ann-Lii
    Meyer, Tim
    Abou-Alfa, Ghassan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [33] Outcomes in patients who had received sorafenib as the only prior systemic therapy in the Phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma
    Strasser, S. I.
    Kelley, R. K.
    Ryoo, B-Y
    Merle, P.
    Park, J-W
    Bolondi, L.
    Chan, S. L.
    Lim, H. Y.
    Baron, A.
    Knox, J.
    Cattan, S.
    Yau, T.
    Lougheed, J. C.
    Milwee, S.
    El-Khoueiry, A. B.
    Cheng, A-L
    Meyer, T.
    Abou-Alfa, G. K.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 21 - 22
  • [34] Clinical activity of cabozantinib in patients with advanced hepatocellular carcinoma previously treated with anti-VEGF and immuno-oncology therapy: subgroup analysis from the phase 3 CELESTIAL trial
    Trojan, J.
    Abou-Alfa, G. K.
    Cheng, A. -L.
    Saletan, S.
    Kelley, R. K.
    El-Khoueiry, A. B.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 124 - 125
  • [35] Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma
    Cheng, A.
    Kang, Y.
    Chen, Z.
    Tsao, C.
    Qin, S.
    Kim, J.
    Burock, K.
    Zou, J.
    Voliotis, D.
    Guan, Z. Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
    Llovet, J.
    Ricci, S.
    Mazzaferro, V.
    Hilgard, P.
    Raoul, J.
    Zeuzem, S.
    Poulin-Costello, M.
    Moscovici, M.
    Voliotis, D.
    Bruix, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [37] Pembrolizumab (pembro) versus placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase 3 KEYNOTE-240 study.
    Finn, Richard S.
    Edeline, Julien
    Bouattour, Mohamed
    Cheng, Ann-Lii
    Chan, Stephen Lam
    Yau, Thomas
    Garrido, Marcelo
    Knox, Jennifer J.
    Daniele, Bruno
    Zhu, Andrew X.
    Breder, Valeriy Vladimirovich
    Lim, Ho Yeong
    Ogasawara, Sadahisa
    Siegel, Abby B.
    Rahman, Ahmadur
    Wei, Ziwen
    Merle, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] Pembrolizumab (pembro) vs placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase III KEYNOTE-240 study.
    Merle, Philippe
    Edeline, Julien
    Bouattour, Mohamed
    Cheng, Ann-Lii
    Chan, Stephen Lam
    Yau, Thomas
    Garrido, Marcelo
    Knox, Jennifer J.
    Daniele, Bruno
    Zhu, Andrew X.
    Breder, Valeriy Vladimirovich
    Lim, Ho Yeong
    Ogasawara, Sadahisa
    Siegel, Abby B.
    Rahman, Ahmadur
    Wei Ziwen
    Finn, Richard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [39] Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: A comparison with previously known prognostic models
    Baek, K.
    Kim, J.
    Um, J.
    Park, S.
    Lee, J.
    Park, J.
    Park, Y.
    Lim, H.
    Kang, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [40] Effect of second-line cabozantinib on health states for patients with advanced hepatocellular carcinoma (aHCC) after sorafenib: QTWiST analysis from the CELESTIAL study
    Freemantle, N.
    Abou-Alfa, G. K.
    Cheng, A-L.
    Kelley, R. K.
    Valcheva, V.
    Benzaghou, F.
    Mollon, P.
    ANNALS OF ONCOLOGY, 2019, 30 : 290 - 290
12345